Skip to main content

Agilent and Bruker Extend Their Proteomics Collaboration

NEW YORK, March 10 (GenomeWeb News) - Agilent Technologies and Bruker Daltonics have extended by several years their ion trap mass spectrometry collaboration and liquid chromatography/capillary electrophoresis OEM agreement, the companies said today.

The amended ITMS collaboration "extends the ion trap-development cooperation, the continued supply of mass spectrometry parts and components from Agilent to Bruker Daltonics, and the end-product manufacturing by Bruker Daltonics of each company's respective ITMS product lines," the firms said.


The deal also enables Bruker Daltonics, an operating company of Bruker BioSciences, to continue incorporating Agilent's atmospheric pressure ionization sources into its line of MS products.

The agreement also "facilitates the introduction of each company's ion trap HCT Ultra and XCT Ultra mass spectrometers."

The extended LC/CE OEM agreement, meantime, "provides for Bruker' ongoing distribution of specific Agilent separation products," including its 1100 Series liquid chromatograph and capillary electrophoresis equipment.


Under the extended agreement, Bruker "may also now OEM the current version of Agilent's revolutionary new HPLC-Chip/MS products with the compatible Bruker Daltonics ITMS and FTMS products."

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.